Physician profile
Tabitha N Brooks
NPI 1619648060
$2,200.04
in general payments reported to CMS, 2019-2025
19 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.95 · 2022: $96.59 · 2023: $467 · 2024: $578 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.55 | 2022-2025 | |
| Braeburn INC. | $271.82 | 2023-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $169.73 | 2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $156.72 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $89.74 | 2024-2025 | Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.82 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.95 | 2021 | |
| Alkermes, INC. | $33.75 | 2022-2025 | Vivitrol |
| Xeris Pharmaceuticals, INC. | $33.05 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $27.82 | 2024 | Rexulti |
| Verona Pharma, INC. | $22.70 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $22.67 | 2025 | Yupelri |
| Indivior INC. | $22.49 | 2025 | Sublocade |
| Lundbeck LLC | $21.99 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $21.70 | 2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $18.01 | 2024 | Omnipod |
| Idorsia Pharmaceuticals US INC | $14.73 | 2022 | |
| Lilly USA, LLC | $13.46 | 2025 | Mounjaro |
| Organon LLC | $9.34 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.